At end of day Thursday, July 12, the CMS released its proposed Medicare Physician Fee Schedule for 2019. The projected rules update rates and policies applicable to Medicare physicians and other professionals under Medicare, and also include updates to Medicare rates and policies under Part B, as well as to the Quality Payment Program which implements the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs).
This is the first year CMS included updates to the Quality Payment Program (QPP) in the proposed fee schedule. This and myriad other changes already have the healthcare industry talking: What do the various changes mean? What is their impact to labs and pathology practices?
Fewer than 145 days remain before your lab will begin to see the financial impact from the new and complicated revisions. To help you and your management team respond in a timely way to these fresh threats, register now to attend “Proposed Changes to the Medicare Physician Fee Schedule and Quality Payment Program Just Released: What You Need to Know and Action Steps to Take Now to Protect Your Lab’s Revenue.” This webinar CD, provides you with an insider’s perspective on the essential market intelligence and knowledge you need to respond to the loss of important revenue that your lab will experience as of January 1.
Absolutely a “must attend” session for pathologists and their laboratory administrators, the webinar is also essential knowledge for all laboratories where Medicare payments are a major source of revenue, and who have a paramount need to maintain the financial solvency of their lab organizations.
The webinar will open with incisive analysis from a foremost expert on this topic, Lâle White, Executive Chairman and CEO, XIFIN, Inc., San Diego, CA. White and her colleagues at XIFIN have access to a remarkable pool of real-world clinical laboratory data, giving White a unique understanding of the subject matter and its potential impact to your laboratory and its financial health, why these changes may be deep and painful to the lab industry as a whole, plus sound recommendations of steps your lab can get started on immediately.
Additional invaluable perspectives and insights will be provided by Kyle Fetter, Executive Vice President and General Manager of Diagnostic Services, and Diana Brooks, Director of Anatomic Pathology Program Development—both of XIFIN, as well as Mick Raich, President and Chief Executive Officer of Vachette Pathology in Blissfield, MI.
DATE: Held Wednesday, August 15, 2018
TIME: 2 p.m. EDT; 1 p.m. CDT; 12 p.m. MDT; 11 a.m. PDT
PLACE: Your computer
COST: $245 per CD
TO ORDER CD: Click here
With your attendance of this webinar, you’ll get the information you need be proactive in your laboratory business, keep your lab profitable, and be armed with the necessary steps you should take to prepare for January 2019. What’s more, for one low price—just $245 per CD—you and your entire team at one location can take part in this valuable learning session.
This timely webinar will help you use the days remaining before the changes take effect to best advantage. Nothing less than the financial health of your pathology practice is at stake—which is why it’s particularly important that you have each and every one of your lab’s management team together to participate.
You can protect your lab’s finances but only if you have the crucial knowledge and information about these proposed changes, in order to prepare the right strategies and action plan.
Executive Chairman and CEO
San Diego, CA
Lâle White is a nationally recognized expert in the field of medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the US. She worked with HCFA and the US Office of the Inspector General to develop the first OIG Model Compliance Program. White was previously Vice President – Finance of Laboratory Corporation of America (NYSE: LH), one of the largest clinical reference laboratories in the US, and its predecessor National Health Laboratories (NYSE: NHLI), where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. She previously served on the Board of Directors for bioTheranostics, part of the worldwide bioMerieux group, and is currently a member of the Board of Directors for CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders.
Kyle Fetter, MBA, BA
Executive Vice President & General Manager of Diagnostic Services
San Diego, CA
Kyle Fetter has implemented and overseen the commercialization, billing, and reimbursement processes for over 70 unique molecular diagnostic companies releasing new high complexity laboratory testing services onto the health care market. He currently provides strategic direction as well as oversees the implementation process for molecular diagnostic companies at various stages of commercialization and third-party payer contracting. He also oversees the development and commercialization of new web-based software products at XIFIN catered to high complexity testing laboratories. In addition to actively working with XIFIN’s large molecular diagnostic billing department, he consults with molecular diagnostic companies on projecting cash flow for non-covered services, implementing successful appeals strategies, and how to effectively manage the relationship between sales and reimbursement for new medical technology. Kyle regularly provides insights into the changing landscape of molecular diagnostic reimbursement via webinars, conferences, and XIFIN’s blog. He came to the healthcare industry with a background in technology funding and commercialization. Kyle has a B.A. from the University of Southern California and an M.B.A from the University of Utah.
Director of Anatomic Pathology Program Development
San Diego, CA
Diana Brooks is the Director of the Anatomic Pathology Program Development at XIFIN, providing strategic support for pathology operations and clients. With more than 14 consecutive years of working in the Pathology and Laboratory industry, Diana has an exceptional understanding of market landscape. She has worked with pathology practices nationwide, helping them to improve their revenue cycle performance, offering direction for growth and development, exploring financially related process improvement opportunities, and developing strategic partnerships with a variety of pathology practices, of all scopes and sizes, around the country. Diana’s previous roles include senior level business development, client management, billing performance analysist, internal auditor, and marketing coordination. Diana holds a B.A. in Marketing as well as Economics from Francis Marion University.
President and Chief Executive Officer
Mick Raich is the founder of Vachette Pathology. He is a nationally recognized consultant in the business of pathology and laboratory billing. His easy style and get-it-done personality have allowed him to become the industry leader in this field.
Mr. Raich has spent his entire 26 year career in healthcare. His experience includes direct patient care, hospital management, and working at a pathology billing company. Since 2001, Mr. Raich has served as the President/CEO of Vachette Pathology.
Over the years Mr. Raich has presented at every major national pathology and laboratory society conference and numerous state societies. He is frequently quoted, interviewed, and published as a specialist in this field. Mr. Raich is an ardent supporter of PathPAC and a member of MGMA.